
==== Front
World J Surg Oncol
World J Surg Oncol
World Journal of Surgical Oncology
1477-7819
BioMed Central London

39232731
3510
10.1186/s12957-024-03510-6
Research
Impact on survival of sarcopenia, systemic inflammatory response and anthropometric factors after pancreatectomy for resectable pancreatic adenocarcinoma
Balcer Kaja kaja.balcer@gmail.com

1
Garnier Jonathan 2
Richa Yasmina 3
Bruneel-Zupanc Christophe 4
Piessen Guillaume 5
Turrini Olivier 2
Truant Stephanie 1
Amrani Mehdi El 1
1 grid.410463.4 0000 0004 0471 8845 Digestive Surgery and Transplantation Department, CHU de Lille, University of Lille, Lille, 59000 France
2 https://ror.org/04s3t1g37 grid.418443.e 0000 0004 0598 4440 Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, 13009 France
3 https://ror.org/03265fv13 grid.7872.a 0000 0001 2331 8773 School of Medicine, University College Cork, Cork, Ireland
4 https://ror.org/05f950310 grid.5596.f 0000 0001 0668 7884 Department of Economics, KU Leuven, Leuven, Belgium
5 grid.410463.4 0000 0004 0471 8845 Department of Digestive and Oncological Surgery, University of Lille, CNRS, INSERM, CHU Lille, University of Lille, Lille, 59000 France
4 9 2024
4 9 2024
2024
22 23226 4 2024
25 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Introduction

Pancreatic adenocarcinoma (PDAC) is becoming a public health issue with a 5-years survival rate around 10%. Patients with PDAC are often sarcopenic, which impacts postoperative outcome. At the same time, overweight population is increasing and adipose tissue promotes tumor related-inflammation. With several studies supporting independently these data, we aimed to assess if they held an impact on survival when combined.

Methods

We included 232 patients from two university hospitals (CHU de Lille, Institut Paoli Calmette), from January 2011 to December 2018, who underwent Pancreaticoduodenectomy (PD) for resectable PDAC. Preoperative CT scan was used to measure sarcopenia and visceral fat according to international cut-offs. Neutrophil to lymphocyte (NLR) and platelet to lymphocyte ratios (PLR) were used to measure inflammation. For univariate and multivariate analyses, the Cox proportional-hazard model was used. P-values below 0.05 were considered significant.

Results

Sarcopenic patients with visceral obesity were less likely to survive than the others in multivariate analysis (OS, HR 1.65, p= 0.043). Cutaneous obesity did not influence survival. We also observed an influence on survival when we studied sarcopenia with visceral obesity (OS, p= 0.056; PFS, p = 0.014), sarcopenia with cutaneous obesity (PFS, p= 0.005) and sarcopenia with PLR (PFS, p= 0.043). This poor prognosis was also found in sarcopenic obese patients with high PLR (OS, p= 0.05; PFS, p= 0.01).

Conclusion

Sarcopenic obesity was associated with poor prognosis after PD for PDAC, especially in patients with systemic inflammation. Pre operative management of these factors should be addressed in pancreatic cancer patients.

Keywords

Pancreatic adenocarcinoma
Sarcopenia
Systemic inflammatory response
Obesity
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Pancreatic adenocarcinoma (PDAC) is the third leading cause of cancer death, with a five-year survival rate of 12 % [1]. Despite advances in chemotherapy and radiotherapy, it is projected to become the second leading cause of cancer- related mortality by 2030 [2]. The underlying cause of PDAC remains unknown, but several risk factors such as genetic predispositions, smoking, alcohol use, chronic pancreatitis, diet, and obesity have been identified [3, 4]. To this day, surgical resection accompanied with perioperative chemotherapy remains the only curative option to treat PDAC [5]. However, this approach is linked to high morbidity and mortality rates [6, 7].

When it comes to surgical treatment of various cancer types, anthropometric factors have been shown to influence patient postoperative survival [8–10]. Notably, some studies have shown that obesity and sarcopenia in PDAC are associated with lower survival rates [11, 12]. According to the European working group on sarcopenia in older people (EWGSOP), sarcopenia is defined by low muscle mass and low muscle strength and is assessed using different cut-offs [13]. Obesity, defined by a body mass index (BMI) superior to 30 kg/m2 is associated with poor health outcomes such as cancer [14]. Sarcopenic obesity is prevalent in today’s population and appears to be increasing with age [12, 15] and measurable with CT-Scan [16].

There has been a recent focus on sarcopenia and inflammation with regards to several malignancies. Previous reports have shown that these factors are interrelated and that they are predictors of poor patient outcomes [17, 18]. Recently, platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) markers have been effectively used to identify systemic inflammatory response (SIR) and to predict post-operative survival in PDAC patients [19].

The aim of this study is to demonstrate the impact of sarcopenia, visceral obesity, sarcopenic obesity, and inflammation status on postoperative oncological outcomes after pancreatoduodenectomy (PD) for PDAC.

Patients and methods

Study population

Participants were identified from the department of digestive and transplant surgery at Lille University Hospital and from the department of surgical oncology at Institut Paoli-Calmette in Marseille. We selected patients who underwent PD for PDAC from the 1st of January 2011 to the 31st of December 2018. Only patients with PDAC comprising of surgically resectable tumors were included in our study. Underage patients, patients treated with neoadjuvant chemotherapy and/or radiotherapy, patients who underwent palliative procedures, and those with low quality CT scans were excluded from our analysis. We believe that being so selective about our patients would be more accurate to study the correlation between sarcopenia, visceral obesity and prognosis. The study complied with French National Health guidelines on research involving human subjects. IRB approval was not needed for this study.

Data collection

Clinical data including demographics, ASA score, Charlson comorbidity score, preoperative body weight, height, BMI, laboratory data, tumor characteristics were retrieved from patients’ medical records. Recorded data comprised of: intraoperative (operative time, blood loss, type of pancreatic anastomosis, vascular reconstruction), histological (histologic classification, degree of differentiation, and resection margin status), postoperative (length of stay, post-operative complications as defined by the Clavien-Dindo classification, and pancreatic surgery complications as defined by guidelines of International Study Group of pancreatic surgery) [20], and follow-up data (adjuvant therapy rate, recurrence rate, overall survival, and disease-free survival).

Muscle mass, subcutaneous and visceral adipose tissue measurements

Preoperative CT scans were performed at least one month prior to the surgery and analyzed using the MYRIAN software. Total abdominal muscle area (TAMA) comprising of transversus abdominis, external and internal obliques, rectus abdominis, psoas muscles and para spinal muscles, was measured on one image slice at vertebral level L3. Subcutaneous fat area (SFA) and visceral fat area (VFA) were also measured using this method. We calculated skeletal muscle index (SMI) as follow: TAMA measured at L3 (cm2) divided by height (m2). Since there is no gold standard cut off for sarcopenia, we used Prado’s cut-offs, based on BMI and SMI. Indeed, their study held a large variability of body composition in cancer patients with statistics to support their number choices [13] : obese (BMI>30 kg/m2) women with SMI<38.5 cm2/m2, non-obese (BMI<30 kg/m2) women with SMI<32 cm2/m2, obese men with SMI<52.4 cm2/m2, and non-obese men with SMI<42 cm2/m2. Visceral obesity was defined as visceral fat area VFA>130 cm2 measured at L3 level. Subcutaneous obesity was classified as high for patients with subcutaneous fat area SFA>177 cm2. In line with other studies, median measures were used as gold-standard cut-offs have yet to be defined [21, 22].

Inflammatory markers

Biological data were collected retrospectively from six-month old laboratory data. As reported in previous studies, NLR>3 was defined as high, and the PLR cut-off was 150 [23–26].

Statistical analysis

Computation was performed using the R software, with significant P-values being lower than 0.05. Continuous variables were compared using student t-test and categorical variables were analyzed using Fisher’s test. The Kaplan-Meier method was used to calculate survival curves that were then compared with the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional-hazard model.

Results

A total of 364 patients underwent PD during the study period. Among them, 88 patients were excluded due to unavailable preoperative CT scans. Of the 276 remaining patients, 20 were excluded as they were previously treated with neoadjuvant therapy and 24 were excluded as their treatment comprised of a procedure different from PD. Of the 232 patients included in our study, 49% were sarcopenic and 10% suffered from sarcopenic obesity. Sarcopenic patients were more likely to have low BMI, SMI, and cutaneous adipose tissue (Table 1). Table 1 Characteristics of the study population

Caracteristics	All patients n = 196	Sarcopenia	
N			No ; n = 98	Yes ; n = 94	
Age$	196	67,47	9,82	67,73	8,69	67,63 (+/10,36)	10,36	
Sex (n male %)**	195	108	55,4	37	37,8	68	72,3	
ASA Score$	196	2,11	0,64	2,08	0,65	2,15	0,62	
Score 0-2 (n(%))		149	76	76	77,6	69	73,4	
Score 3-4 (n(%))	47	24	22	22,4	25	26,6	
Charlson$	115	2,96	1,55	3,24	1,49	2,73	1,59	
Score 0-2 (n(%))		45	39,13	18	30,5	24	46,15	
Score 3-4 (n(%))	52	45,22	28	47,5	23	44,23	
Score >4 (n(%))	18	15,65	13	22	5	9,62	
Medical history (n(%))	
 High blood pressure	133	63	47,4	37	54,4	23	37,7	
 Ischemic heart disease	114	12	10,5	8	13,8	4	7,7	
 Heart failure	114	1	0,9	0	0	1	1,9	
 Kidney failure	114	1	0,9	1	1,7	0	0	
 COPD*	115	4	3,5	4	6,8	0	0	
 Respiratory failure	114	0	0	0	0	0	0	
 Chronic pancreatitis	113	6	5,3	3	5,3	3	5,8	
 Diabetes	133	31	23,3	18	26,5	12	19,7	
 Cirrhosis	103	1	1	1	2	0	0	
Discovery circumstances (n(%))	
 Abdominal pain	112	57	50,9	31	54,4	25	49	
 Jaundice	114	80	70,2	41	70,7	36	69,2	
 Acute cholitis	110	8	7,3	3	5,5	4	7,8	
 Worsening diabetes	111	10	9	7	12,5	3	5,9	
 Pancreatitis	113	19	17,1	8	14,3	11	21,6	
Malnutrition (n(%))	115		
moderate		51	44,35	23	39	26	50	
severe		29	25,22	15	25,4	13	25	
BMI$**	192	24,54	4,13	26,10	4,34	22,82	3,19	
SMI$**__	193	46,46	13,08	52,77	12,48	39,87	10,23	
Sarcopenia (n (%))	192	94	49	0	0	1	100	
Cutaneous fat (cm2/m2)$**	196	197	99	240,46	102,96	148,73	68,36	
Visceral fat (cm2/m2)$*	193	146	94	159,67	95,22	129,45	88,03	
Ca 19-9$	81	495,79	851	430,37	874,58	562,04	853,97	
Albumin$	115	37,03	6,24	37,7	5,86	36,81	6	
Pre-albumin$	114	0,19	0,07	0,19	0,07	0,20	0,08	
CRP$	85	17,90	29,90	16,77	25,6	19,10	34,26	
NLR$	161	3,50	2,35	3,17	2,26	3,78	2,40	
PLR$	160	181,09	98,22	171,4	84,85	191,3	109,08	
Post operative complications :	
 Clavien Dindo > 3a (n(%))	130	28	21,5	17	24,6	11	18,6	
Anatomopathology	
 pT (n(%))	192		
 pT1-pT2		51	26,6	30	31,2	21	22,6	
 pT3-pT4		141	73,4	66	68,8	72	77,4	
 Vascular embolus (n(%))	154	65	42,2	28	36,4	36	48,6	
 Lymphatic embolus (n(%))	108	20	18,5	9	16,7	9	17,6	
Resection (n(%))	194		
R0		169	87,1	86	87,8	80	86	
R1		24	12,4	11	11,2	13	14	
R2		1	0,5	1	1	0	0	
N+$	189	2,47	2,64	2,37	2,75	2,54	2,5	
N+/N$	189	0,19	0,43	0,20	0,58	0,17	0,18	
Adjuvant chemotherapy (n(%))	112		83,9	46	80,7	44	86,3	
Mortality at 90 days (n(%))	196	8	4,1	5	5,1	3	3,2	
Dead (n(%))	196	135	69	64	65,3	69	73,4	
Days before death$	196	636	478	656	534	626	427	
Survival in days$	196	1074	876	1164	959	969	764	
ASA American society of anesthesiologists, COPD Chronic obstructive pulmonary disease, BMI Body mass index, SMI Squeletal muscle index, NLR Neutrophil to lymphocyte ratio, PLR Platelet to lymphocyte ratio

$= mean (+/- SD)

*= p-value < 0,005

**= p-value < 0,001

We studied the correlation between sarcopenia and inflammatory markers. No correlation was observed between sarcopenia and NLR or PLR. However, sarcopenic patients tended to present with higher NLR and PLR compared to non-sarcopenic patients.

Moreover, we assessed the impact of sarcopenia, NLR and PLR on oncological outcomes after PD for PDAC. Sarcopenic patients were shown to have a lower progression-free survival (PFS) compared to non-sarcopenic patients (p=0.09). However, overall survival (OS) was similar for sarcopenic patients and non-sarcopenic patients (p=0.2). Regarding inflammatory status, no significant differences were observed in PFS and OS between patients with high NLR and those with low NLR. Similar results were observed regarding PLR status. With regards to obesity status, OS and OFS were not impacted by VFA and SFA after PD for PDAC.

We then investigated patients’ survival outcomes based on their sarcopenia and inflammatory status. We found that sarcopenic patients with high NLR tended to have worse prognosis than non-sarcopenic patients with high NLR, but that the difference was not significant (Fig. 1A). However, PFS was significantly lower for sarcopenic patients with high PLR compared to non-sarcopenic patients with low PLR (p=0.043). Moreover, OS appeared to be lower for sarcopenic patients with high PLR compared to non-sarcopenic patients with low PLR (p=0.096) (Fig. 1B).Fig. 1 Survival outcome based on sarcopenia and inflammatory status, A Survival in sarcopenic and non-sarcopenic patients with high or low NLR, B Survival in sarcopenic and non- sarcopenic patients with high or low PLR

Furthermore, we quantified the impact of sarcopenia and obesity on survival. Patients who were classified as sarcopenic and viscerally obese demonstrated lower survival rates compared to non-sarcopenic and non-obese patients (OS, p= 0.014; PFS, p=0.05) (Fig. 2A). Furthermore, sarcopenic patients with cutaneous obesity had a lower PFS (p = 0.0059) compared to non-sarcopenic and non-cutaneous obese patients (Fig. 2B).Fig. 2 Survival outcome based on sarcopenia and obesity, A Survival in sarcopenic and non-sarcopenic patients with visceral obesity, B Survival in sarcopenia and non-sarcopenic patients with cutaneous obesity

Among our study participants, 20 were considered sarcopenic, viscerally obese, and had a high NLR. Although the difference is not significant, these patients had lower rates of OS and PFS compared to non-sarcopenic, non-obese patients with low NLR. Moreover, sarcopenic obesity in patients with high PLR had a lower PFS (p=0.01) and OS (p=0.05) compared to non-sarcopenic, non-obese patients with low PLR (Fig. 3).Fig. 3 Survival outcome based on sarcopenia, visceral obesity and PLR status, A Progression free survival, B Overall survival

Finally, a multivariate analysis with Cox proportional-hazard ratio was performed to identify the risk factors of worse prognosis after PD for PDAC. Based on the multivariate analysis, the sarcopenic visceral obesity variable was independent from poor prognostic factors. The result was significant for OS (HR, 2.17; 95% CI,1.2–4.6, p=0.04) (Fig. 4A) and PFS (HR, 2.34; 95% CI,1.16–4.7, p=0.018). Lastly, lower PFS was associated with high PLR and cutaneous obesity (p= 0.08 and p= 0,064 respectively) (Fig. 4B).Fig. 4 Multivariate analysis (COX Proportional Hazard ratio model, p= 0,05), A Overall survival, B Progression free Survival

Discussion

This study is the first to examine the relationship between SIR, sarcopenia, and visceral obesity in PDAC. Our results demonstrate an interdependence between inflammation and sarcopenia and highlight their impact on positive patient outcomes. Interestingly, we found that sarcopenic patients with visceral obesity were more likely to relapse following PDAC and presented reduced post-operative survival. Our data suggests that preoperative evaluation of sarcopenia, inflammation and visceral obesity status could help to determine postoperative patient outcomes and thus assess if a patient is an appropriate candidate for surgery.

Based on our results, sarcopenia alone does not impact oncological outcomes after PD for PDAC (OS, p= 0.2; PFS, P= 0.09). Several papers have identified sarcopenia as a risk factor for poor prognosis in many cancers including PDAC [10]. Previous research suggest that tumor aggressiveness is correlated with sarcopenic status [26]. Leads on decreasing sarcopenia have been established, but the data is lacking for patients undergoing PD. Physical training against resistance and improved nutrition (nutritional supplements by vitamin D, ß-methylbutyrate and creatine) up to three months before surgery have been proposed to enhance post-operative survival [27, 28]. Several randomized controlled studies to identify an adequate preoperative program for sarcopenic patients before highly complex procedures are in progress.

In cancer patients, sarcopenia is frequently associated with inflammation. Indeed, tumors create an inflammatory environment by producing diverse cytokines, altering local balance, and attracting neutrophils [29]. Moreover, chronic inflammation generates neoplastic processes by inducing DNA damage [30]. It has been suggested that PLR is a useful prognostic factor in some cancer types since platelets enhance tumor development by promoting angiogenesis through the cytokine vascular endothelial growth factor (VEGF). Due to the involvement of lymphocytes and neutrophils in PDAC and the tumoral microenvironment, NLR has also been associated with PDAC survival [31, 32]. NLR has been used as a prognostic factor in several cancers [33–35] including PDAC [35]. When NLR is highly elevated, surgery should be delayed, and neoadjuvant treatment should be prioritized. In fact, neoadjuvant chemotherapy has been shown to lower NLR and improve postoperative prognosis in patients with breast cancer [34]. Moreover, the normalization of PLR and NLR after the first cure of FOLFOX in patients with gastric cancer was associated with better OS [36]. As previously reported, these findings indicate that sarcopenia and inflammation reflect aggressive tumor process [16, 37, 38].

Our investigation also focused on the impact of VFA and SFA on PDAC prognosis. Our results suggest that visceral and subcutaneous obesity do not impact patient survival. Nonetheless, sarcopenic and viscerally obese patients had poorer OS and PFS, regardless of their BMI. Similarly, Okumura et al. reported that sarcopenic visceral obesity is closely associated with mortality and recurrence [16, 39, 40]. These findings demonstrate that the redistribution of muscle mass and adipose tissue is a key factor to consider when predicting patient prognosis. An emerging topic about fat distribution is myosteatosis and its association with sarcopenia. More studies are reporting the influence of muscle fat on muscle strength and physical activity leading to a worse post operative prognosis in cancer patients regardless of sarcopenia [41, 42].

Our results highlight the prognostic role of sarcopenic visceral obesity associated with inflammation in patients with PDAC. Visceral fat increases proinflammatory cytokine levels, leading to chronic inflammation and consequently increased carcinogenesis [43, 44]. Moreover, adipokines and myokines affect the immune system and promote inflammation [43]. Thus, visceral adiposity, loss of muscle mass, and inflammation are interrelated factors that predict poor patient outcomes [45].

Our study presented some limitations. First, the retrospective study design can be subject to bias, suggesting the need for a prospective study in the future. Second, cut-offs to define sarcopenia, visceral obesity, and inflammation in patients with PDAC were not previously validated due to the lack of a current consensual definition [46]. Third, our analysis only focused on patients undergoing PD, preventing generalization of our results to other treatments or surgical interventions. Finally, sarcopenia was assessed based on preoperative CT scan by measuring the TAMA. In the future, more effective methods could be used to determine sarcopenic state such as dual X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA) [47].

Sarcopenic obesity and SIR are associated with poorer patient outcomes and lower survival rates. Our results suggest that the prognosis of pancreatic cancer patients can be improved with various treatment adjustments. Sarcopenia, visceral obesity, and inflammatory status being predictive of poor prognosis, patients who are assessed for these factors should be considered borderline resectable PDAC and should be treated with neoadjuvant chemotherapy [45]. When sarcopenia is screened for in daily practice, the importance of nutritional care and exercising should be explained to patients. Nutrition can be improved with adequate protein intake of 1.2 g/kg/day. Progressive resistance training (PRT) [48] and supplementation can improve muscle mass, muscle strength and physical performance [47, 49, 50]. Our analysis provides a framework for assessing patient preoperative parameters to determine the most appropriate treatment approach for resectable PDAC. Several protocols can be implemented to improve patient survival and should include exercise,

nutrition modification or neoadjuvant chemotherapy. Further studies should be performed to assess the efficiency of these measures in determining PDAC treatment outcomes.

Authors’ contributions

KB wrote the entire Manuscript. MEA contributed by helping with the structure of the research, the data, the in-site reviewing. YR contributed by reading and correcting the final form of the manuscript. CAB contributed by helping doing the statistics after the data were collected. ST, GP, OT and JG contributed by letting me access the patients' data.

Funding

No fundings were received by authors for this word.

Availability of data and materials

Some data are available.

Data availability

Data that support the findings of this study were collected from the onsite hospital software (in Lille and Marseille).

Declarations

Ethics approval and consent to participate

The study complied with French National Health guidelines on research involving human subjects. IRB approval was not needed for this study.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Siegel RL Miller KD Wagle NS Jemal A Cancer statistics, 2023 CA Cancer J Clin. 2023 73 1 17 48 10.3322/caac.21763 36633525
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. 10.3322/caac.21763. PMID: 36633525.36633525 10.3322/caac.21763
2. Gordon-Dseagu VL Devesa SS Goggins M Stolzenberg-Solomon R Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data Int J Epidemiol. 2018 47 2 427 439 10.1093/ije/dyx232 29149259
Gordon-Dseagu VL, Devesa SS, Goggins M, Stolzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47(2):427–39. 10.1093/ije/dyx232. PMID: 29149259; PMCID: PMC5913617.29149259 10.1093/ije/dyx232
3. Ilic M Ilic I Epidemiology of pancreatic cancer World J Gastroenterol. 2016 22 44 9694 705 10.3748/wjg.v22.i44.9694 27956793
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–705.27956793 10.3748/wjg.v22.i44.9694
4. Becker AE Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection WJG. 2014 20 32 11182 10.3748/wjg.v20.i32.11182 25170203
Becker AE. Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection. WJG. 2014;20(32):11182.25170203 10.3748/wjg.v20.i32.11182
5. Principe DR Underwood PW Korc M Trevino JG Munshi HG Rana A The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy Front Oncol. 2021 11 688377 10.3389/fonc.2021.688377 34336673
Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Front Oncol. 2021;11:688377.34336673 10.3389/fonc.2021.688377
6. El Amrani M Clement G Lenne X Farges O Delpero JR Theis D Failure-to-rescue in patients undergoing pancreatectomy: is hospital volume a standard for quality improvement programs? Nationwide analysis of 12,333 patients Ann Surg 2018 268 5 799 807 10.1097/SLA.0000000000002945 30048329
El Amrani M, Clement G, Lenne X, Farges O, Delpero JR, Theis D, et al. Failure-to-rescue in patients undergoing pancreatectomy: is hospital volume a standard for quality improvement programs? Nationwide analysis of 12,333 patients. Ann Surg. 2018;268(5):799–807.30048329 10.1097/SLA.0000000000002945
7. El Amrani M Lenne X Clément G Turrini O Theis D Pruvot FR Referring patients to expert centers after pancreatectomy is too late to improve outcome. Inter-hospital transfer analysis in nationwide study of 19,938 patients Ann Surg. 2020 272 5 723 30 10.1097/SLA.0000000000004342 32833752
El Amrani M, Lenne X, Clément G, Turrini O, Theis D, Pruvot FR, et al. Referring patients to expert centers after pancreatectomy is too late to improve outcome. Inter-hospital transfer analysis in nationwide study of 19,938 patients. Ann Surg. 2020;272(5):723–30.32833752 10.1097/SLA.0000000000004342
8. Lin J Zhang W Huang Y Chen W Wu R Chen X Sarcopenia is associated with the neutrophil/lymphocyte and platelet/lymphocyte ratios in operable gastric cancer patients: a prospective study CMAR. 2018 10 4935 44 10.2147/CMAR.S175421
Lin J, Zhang W, Huang Y, Chen W, Wu R, Chen X, et al. Sarcopenia is associated with the neutrophil/lymphocyte and platelet/lymphocyte ratios in operable gastric cancer patients: a prospective study. CMAR. 2018;10:4935–44.10.2147/CMAR.S175421
9. Mungan İ Dicle ÇB Bektaş Ş Sarı S Yamanyar S Çavuş M Does the preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict morbidity after gastrectomy for gastric cancer? Military Med Res 2020 7 1 9 10.1186/s40779-020-00234-y
Mungan İ, Dicle ÇB, Bektaş Ş, Sarı S, Yamanyar S, Çavuş M, et al. Does the preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict morbidity after gastrectomy for gastric cancer? Military Med Res. 2020;7(1):9.10.1186/s40779-020-00234-y
10. El Amrani M Vermersch M Fulbert M Prodeau M Lecolle K Hebbar M Impact of sarcopenia on outcomes of patients undergoing pancreatectomy: a retrospective analysis of 107 patients Medicine (Baltimore). 2018 97 39 e12076 10.1097/MD.0000000000012076 30278487
El Amrani M, Vermersch M, Fulbert M, Prodeau M, Lecolle K, Hebbar M, et al. Impact of sarcopenia on outcomes of patients undergoing pancreatectomy: a retrospective analysis of 107 patients. Medicine (Baltimore). 2018;97(39):e12076.30278487 10.1097/MD.0000000000012076
11. Matsunaga T Miyata H Sugimura K Motoori M Asukai K Yanagimoto Y Prognostic significance of sarcopenia and systemic inflammatory response in patients with esophageal cancer Anticancer Res 2019 39 1 449 58 10.21873/anticanres.13133 30591494
Matsunaga T, Miyata H, Sugimura K, Motoori M, Asukai K, Yanagimoto Y, et al. Prognostic significance of sarcopenia and systemic inflammatory response in patients with esophageal cancer. Anticancer Res. 2019;39(1):449–58.30591494 10.21873/anticanres.13133
12. Stenholm S Harris TB Rantanen T Visser M Kritchevsky SB Ferrucci L Sarcopenic obesity - definition, etiology and consequences Curr Opin Clin Nutr Metab Care. 2008 11 6 693 700 10.1097/MCO.0b013e328312c37d 18827572
Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity - definition, etiology and consequences. Curr Opin Clin Nutr Metab Care. 2008;11(6):693–700.18827572 10.1097/MCO.0b013e328312c37d
13. Prado CM Lieffers JR McCargar LJ Reiman T Sawyer MB Martin L Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study Lancet Oncol 2008 9 7 629 35 10.1016/S1470-2045(08)70153-0 18539529
Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35.18539529 10.1016/S1470-2045(08)70153-0
14. Salaün H Thariat J Vignot M Merrouche Y Vignot S Obésité et cancer Bull Cancer 2017 104 1 30 41 10.1016/j.bulcan.2016.11.012 28007295
Salaün H, Thariat J, Vignot M, Merrouche Y, Vignot S. Obésité et cancer. Bull Cancer. 2017;104(1):30–41.28007295 10.1016/j.bulcan.2016.11.012
15. Elia M Ritz P Stubbs RJ Total energy expenditure in the elderly Eur J Clin Nutr 2000 54 3 S92 103 10.1038/sj.ejcn.1601030 11041080
Elia M, Ritz P, Stubbs RJ. Total energy expenditure in the elderly. Eur J Clin Nutr. 2000;54(3):S92–103.11041080 10.1038/sj.ejcn.1601030
16. Okumura S Kaido T Hamaguchi Y Kobayashi A Shirai H Yao S Visceral adiposity and sarcopenic visceral obesity are associated with poor prognosis after resection of pancreatic cancer Ann Surg Oncol. 2017 24 12 3732 40 10.1245/s10434-017-6077-y 28871520
Okumura S, Kaido T, Hamaguchi Y, Kobayashi A, Shirai H, Yao S, et al. Visceral adiposity and sarcopenic visceral obesity are associated with poor prognosis after resection of pancreatic cancer. Ann Surg Oncol. 2017;24(12):3732–40.28871520 10.1245/s10434-017-6077-y
17. Cespedes Feliciano EM Kroenke CH Meyerhardt JA Prado CM Bradshaw PT Kwan ML Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study JAMA Oncol. 2017 3 12 e172319 10.1001/jamaoncol.2017.2319 28796857
Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, et al. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. JAMA Oncol. 2017;3(12):e172319.28796857 10.1001/jamaoncol.2017.2319
18. Fearon KC Glass DJ Guttridge DC Cancer cachexia: mediators, signaling, and metabolic pathways Cell Metab. 2012 16 2 153 66 10.1016/j.cmet.2012.06.011 22795476
Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153–66. 10.1016/j.cmet.2012.06.011. Epub 2012 Jul 12.22795476 10.1016/j.cmet.2012.06.011
19. Yang JJ Hu ZG Shi WX Deng T He SQ Yuan SG Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis World J Gastroenterol. 2015 21 9 2807 15 10.3748/wjg.v21.i9.2807 25759553
Yang JJ, Hu ZG, Shi WX, Deng T, He SQ, Yuan SG. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroenterol. 2015;21(9):2807–15.25759553 10.3748/wjg.v21.i9.2807
20. Bassi C Marchegiani G Dervenis C Sarr M Abu Hilal M Adham M The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After Surgery 2017 161 3 584 91 10.1016/j.surg.2016.11.014 28040257
Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–91.28040257 10.1016/j.surg.2016.11.014
21. Heus C Cakir H Lak A Doodeman HJ Houdijk AP Visceral obesity, muscle mass and outcome in rectal cancer surgery after neo-adjuvant chemo-radiation Int J Surg. 2016 29 159 64 10.1016/j.ijsu.2016.03.066 27063857
Heus C, Cakir H, Lak A, Doodeman HJ, Houdijk AP. Visceral obesity, muscle mass and outcome in rectal cancer surgery after neo-adjuvant chemo-radiation. Int J Surg. 2016;29:159–64. 10.1016/j.ijsu.2016.03.066. Epub 2016 Apr 6.27063857 10.1016/j.ijsu.2016.03.066
22. Antoun S Bayar A Ileana E Laplanche A Fizazi K di Palma M High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting Eur J Cancer. 2015 51 17 2570 7 10.1016/j.ejca.2015.07.042 26278649
Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, di Palma M, et al. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer. 2015;51(17):2570–7.26278649 10.1016/j.ejca.2015.07.042
23. Templeton AJ McNamara MG Šeruga B Vera-Badillo FE Aneja P Ocaña A Leibowitz-Amit R Sonpavde G Knox JJ Tran B Tannock IF Amir E Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis J Natl Cancer Inst. 2014 106 6 dju124 10.1093/jnci/dju124 24875653
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.24875653 10.1093/jnci/dju124
24. Yang JJ Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis WJG. 2015 21 9 2807 10.3748/wjg.v21.i9.2807 25759553
Yang JJ. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. WJG. 2015;21(9):2807.25759553 10.3748/wjg.v21.i9.2807
25. Zhou Y Wei Q Fan J Cheng S Ding W Hua Z Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients Clin Chim Acta 2018 479 181 9 10.1016/j.cca.2018.01.024 29407690
Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients. Clin Chim Acta. 2018;479:181–9.29407690 10.1016/j.cca.2018.01.024
26. Li B Zhou P Liu Y Wei H Yang X Chen T Platelet-to-lymphocyte ratio in advanced Cancer: review and meta-analysis Clin Chim Acta 2018 483 48 56 10.1016/j.cca.2018.04.023 29678631
Li B, Zhou P, Liu Y, Wei H, Yang X, Chen T, et al. Platelet-to-lymphocyte ratio in advanced Cancer: review and meta-analysis. Clin Chim Acta. 2018;483:48–56.29678631 10.1016/j.cca.2018.04.023
27. Coussens LM Werb Z Inflammation and cancer Nature. 2002 420 6917 860 7 10.1038/nature01322 12490959
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.12490959 10.1038/nature01322
28. Lobo DN Gianotti L Adiamah A Barazzoni R Deutz NEP Dhatariya K Perioperative nutrition: recommendations from the ESPEN expert group Clin Nutr 2020 39 11 3211 27 10.1016/j.clnu.2020.03.038 32362485
Lobo DN, Gianotti L, Adiamah A, Barazzoni R, Deutz NEP, Dhatariya K, et al. Perioperative nutrition: recommendations from the ESPEN expert group. Clin Nutr. 2020;39(11):3211–27.32362485 10.1016/j.clnu.2020.03.038
29. Baazim H Antonio-Herrera L Bergthaler A The interplay of immunology and cachexia in infection and cancer Nat Rev Immunol 2022 22 5 309 21 10.1038/s41577-021-00624-w 34608281
Baazim H, Antonio-Herrera L, Bergthaler A. The interplay of immunology and cachexia in infection and cancer. Nat Rev Immunol. 2022;22(5):309–21.34608281 10.1038/s41577-021-00624-w
30. Kay J Thadhani E Samson L Engelward B Inflammation-induced DNA damage, mutations and cancer DNA Repair 2019 83 102673 10.1016/j.dnarep.2019.102673 31387777
Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair. 2019;83:102673.31387777 10.1016/j.dnarep.2019.102673
31. Pointer DT Roife D Powers BD Murimwa G Elessawy S Thompson ZJ Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma BMC Cancer. 2020 20 1 750 10.1186/s12885-020-07182-9 32782024
Pointer DT, Roife D, Powers BD, Murimwa G, Elessawy S, Thompson ZJ, et al. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma. BMC Cancer. 2020;20(1):750.32782024 10.1186/s12885-020-07182-9
32. Hong X Cui B Wang M Yang Z Wang L Xu Q Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer Tohoku J Exp Med. 2015 236 4 297 304 10.1620/tjem.236.297 26250537
Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med. 2015;236(4):297–304. 10.1620/tjem.236.297. PMID: 26250537.26250537 10.1620/tjem.236.297
33. Lorite MJ Cariuk P Tisdale MJ Induction of muscle protein degradation by a tumour factor Br J Cancer. 1997 76 8 1035 40 10.1038/bjc.1997.504 9376263
Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer. 1997;76(8):1035–40.9376263 10.1038/bjc.1997.504
34. Choi H Noh H Cho IJ Lim ST Han A Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients’ survival Breast Cancer 2020 27 5 871 9 10.1007/s12282-020-01083-2 32221862
Choi H, Noh H, Cho IJ, Lim ST, Han A. Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients’ survival. Breast Cancer. 2020;27(5):871–9.32221862 10.1007/s12282-020-01083-2
35. Zhou Y Wei Q Fan J Cheng S Ding W Hua Z Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients Clin Chim Acta 2018 479 181 9 10.1016/j.cca.2018.01.024 29407690
Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients. Clin Chim Acta. 2018;479:181–9.29407690 10.1016/j.cca.2018.01.024
36. Lee S Oh SY Kim SH Lee JH Kim MC Kim KH Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy BMC Cancer. 2013 13 350 10.1186/1471-2407-13-350 23876227
Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;13:350.23876227 10.1186/1471-2407-13-350
37. Kawada T Neutrophil-to-lymphocyte ratio as an indicator of prognosis in patients with pancreatic cancer HPB 2019 21 12 1791 10.1016/j.hpb.2019.06.010 31320242
Kawada T. Neutrophil-to-lymphocyte ratio as an indicator of prognosis in patients with pancreatic cancer. HPB. 2019;21(12):1791.31320242 10.1016/j.hpb.2019.06.010
38. Shusterman M Jou E Kaubisch A Chuy JW Rajdev L Aparo S The neutrophil-to-lymphocyte ratio is a prognostic biomarker in an ethnically diverse patient population with advanced pancreatic cancer J Gastrointest Canc 2020 51 3 868 76 10.1007/s12029-019-00316-8
Shusterman M, Jou E, Kaubisch A, Chuy JW, Rajdev L, Aparo S, et al. The neutrophil-to-lymphocyte ratio is a prognostic biomarker in an ethnically diverse patient population with advanced pancreatic cancer. J Gastrointest Canc. 2020;51(3):868–76.10.1007/s12029-019-00316-8
39. Moon HG Ju YT Jeong CY Jung EJ Lee YJ Hong SC Visceral obesity may affect oncologic outcome in patients with colorectal cancer Ann Surg Oncol. juill 2008 15 7 1918 22 10.1245/s10434-008-9891-4
Moon HG, Ju YT, Jeong CY, Jung EJ, Lee YJ, Hong SC, et al. Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol juill. 2008;15(7):1918–22.10.1245/s10434-008-9891-4
40. Fujiwara N Nakagawa H Kudo Y Tateishi R Taguri M Watadani T Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma J Hepatol 2015 63 1 131 40 10.1016/j.jhep.2015.02.031 25724366
Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63(1):131–40.25724366 10.1016/j.jhep.2015.02.031
41. Kim DW Ahn H Kim KW Lee SS Kim HJ Ko Y Park T Lee J Prognostic value of sarcopenia and myosteatosis in patients with resectable pancreatic ductal adenocarcinoma Korean J Radiol. 2022 23 11 1055 1066 10.3348/kjr.2022.0277 36098341
Kim DW, Ahn H, Kim KW, Lee SS, Kim HJ, Ko Y, Park T, Lee J. Prognostic value of sarcopenia and myosteatosis in patients with resectable pancreatic ductal adenocarcinoma. Korean J Radiol. 2022;23(11):1055–66. 10.3348/kjr.2022.0277. Epub 2022 Aug 31. PMID: 36098341; PMCID: PMC9614291.36098341 10.3348/kjr.2022.0277
42. Rollins KE Tewari N Ackner A Awwad A Madhusudan S Macdonald IA The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma Clin Nutr 2016 35 5 1103 9 10.1016/j.clnu.2015.08.005 26411749
Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, Macdonald IA, et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2016;35(5):1103–9.26411749 10.1016/j.clnu.2015.08.005
43. Lutz CT Quinn LS Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism Aging (Albany NY). 2012 4 8 535 46 10.18632/aging.100482 22935594
Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY). 2012;4(8):535–46.22935594 10.18632/aging.100482
44. White PB True EM Ziegler KM Wang SS Swartz-Basile DA Pitt HA Insulin, leptin, and tumoral adipocytes promote murine pancreatic cancer growth J Gastrointest Surg 2010 14 12 1888 94 10.1007/s11605-010-1349-x 20859700
White PB, True EM, Ziegler KM, Wang SS, Swartz-Basile DA, Pitt HA, et al. Insulin, leptin, and tumoral adipocytes promote murine pancreatic cancer growth. J Gastrointest Surg. 2010;14(12):1888–94.20859700 10.1007/s11605-010-1349-x
45. Isaji S Mizuno S Windsor JA Bassi C Fernández-Del Castillo C Hackert T Hayasaki A Katz MHG Kim SW Kishiwada M Kitagawa H Michalski CW Wolfgang CL International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017 Pancreatology. 2018 18 1 2 11 10.1016/j.pan.2017.11.011 29191513
Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW, Kishiwada M, Kitagawa H, Michalski CW, Wolfgang CL. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11. 10.1016/j.pan.2017.11.011. Epub 2017 Nov 22 PMID: 29191513.29191513 10.1016/j.pan.2017.11.011
46. van der Werf A, Langius JAE, de van der Schueren MAE, Nurmohamed SA, van der Pant KAMI, Blauwhoff-Buskermolen S, et al. Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy Caucasian population. Eur J Clin Nutr. 2018.
47. Beaudart C McCloskey E Bruyère O Cesari M Rolland Y Rizzoli R Sarcopenia in daily practice: assessment and management BMC Geriatr. 2016 16 170 10.1186/s12877-016-0349-4 27716195
Beaudart C, McCloskey E, Bruyère O, Cesari M, Rolland Y, Rizzoli R, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16:170.27716195 10.1186/s12877-016-0349-4
48. Liu C Latham NK Progressive resistance strength training for improving physical function in older adults Cochrane Database Syst Rev. 2009 2009 3 CD002759 19588334
Liu C, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009;2009(3):CD002759.19588334
49. Denison HJ Cooper C Sayer AA Robinson SM Prevention and optimal management of sarcopenia: a review of combined exercise and nutrition interventions to improve muscle outcomes in older people Clin Interv Aging. 2015 10 859 69 25999704
Denison HJ, Cooper C, Sayer AA, Robinson SM. Prevention and optimal management of sarcopenia: a review of combined exercise and nutrition interventions to improve muscle outcomes in older people. Clin Interv Aging. 2015;10:859–69.25999704
50. Holeček M Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions J Cachexia Sarcopenia Muscle 2017 8 4 529 41 10.1002/jcsm.12208 28493406
Holeček M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions. J Cachexia Sarcopenia Muscle. 2017;8(4):529–41.28493406 10.1002/jcsm.12208
